Would you continue or switch therapy for someone who progressed through AR directed therapy and has a rapid rise in PSA while receiving Ra-223 for bone-dominant castrate resistant prostate cancer?

Certainly, it is reasonable to stop an AR inhibitor that is no longer clinically benefiting a patient irrespective of the use of concurrent radium-223, particularly a second AR inhibitor if there is no evidence of a response. Cross resistance between AR inhibitors is common and a rapid PSA rise sugg...